Immunotherapy

Immunotherapy is a type of cancer treatment that helps the immune system recognize, attack, or control cancer cells. Unlike chemotherapy and some other treatments that directly damage rapidly growing cancer cells, immunotherapy works by activating or redirecting the body’s immune response. The purpose and effectiveness of immunotherapy vary by cancer type, stage, biomarkers, overall health, and other individual factors.

How does immunotherapy work?

Immunotherapy can remove signals that allow cancer cells to hide from immune defenses or can add immune-based tools that help target the cancer. It may be used alone or combined with chemotherapy, radiation, targeted therapy, surgery, or other cancer treatments when recommended by the oncology team. Because immunotherapy includes several different approaches, the best option depends on the person’s diagnosis and treatment plan.

Immunotherapy for cancer is used for selected cancers, including some lung cancers, other solid tumors, and blood cancers. Whether it is appropriate depends on treatment approvals, the cancer’s type and stage, biomarker findings, previous treatment, and the person’s overall health. For this reason, cancer immunotherapy is not suitable for everyone with the same diagnosis.

In advanced disease, immunotherapy can produce long-lasting responses for some people, but a response cannot be guaranteed. Immunotherapy should not be assumed to cure stage 4 cancer; the oncology team discusses the likely benefits, limitations, and alternatives for each person.

Immunotherapy drugs are not one interchangeable group. Checkpoint inhibitors help release immune system brakes, immune system modulators change immune activity, and monoclonal antibodies attach to specific targets. Cancer vaccines may be used in certain settings, while cellular immunotherapies use specially prepared immune cells; the available option depends on the cancer and approved treatment indications.

A clinician chooses the specific drug, dose, combination, and duration according to the approved indication, the person’s response, and safety monitoring. Immunotherapy versus chemotherapy is not a question of one treatment being universally better; the oncology team weighs the expected benefits and risks for the individual.

Immunotherapy may be delivered through an intravenous infusion, an injection, an oral medicine, a topical treatment, or a cellular therapy process when relevant. Not every method applies to every patient, and the delivery method depends on the specific treatment and cancer diagnosis.

What happens during a treatment visit?

Before treatment, the team may review symptoms and medicines, check vital signs, and order blood tests or other laboratory checks. The treatment is then administered, followed by observation when needed. Sessions may occur at planned intervals in cycles or as ongoing treatment, and the oncology team may adjust, pause, or stop therapy based on side effects, test results, and signs of response.

Immune-related adverse effects

Recovery between immunotherapy sessions varies. Fatigue and other effects may continue between visits, and some immune-related side effects can begin during treatment or after it ends. Follow the oncology team’s instructions about activity, medicines, hydration, testing, and when to report symptoms.

How is treatment response monitored?

Clinicians assess response using symptoms, physical examinations, blood tests, imaging, and other cancer-specific evaluations. Signs immunotherapy is working may include improved symptoms or stable imaging, but these findings alone do not prove that treatment is effective. The oncology team interprets the full picture and uses it to guide the next treatment decision.